US Stock Market Closed

Dashboard

Geron Corp. (GERN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

CEO

John A. Scarlett

Employees

46

Industry

Scientific Products

Sector

Healthcare

Headquarters

Menlo Park

Exchange

NASDAQ

Summary Stats

Market Cap

846M

Revenue

1.53M

Net Income

-131M

EPS

-$0.36

Price-to-Earnings

-6.22

Price-to-Book

7.82

Debt-to-Equity

1.15

News

Analyst Ratings

Price targets projected by 6 analysts

High

$7.00

Average

$4.00

Low

$3.00

Ratings calculated by 6 analysts

Buy

6

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by -$0.01

Actual

-$0.10 -11.1%

Consensus

-0.09

Report Date

Year Ago

-0.08

Year Ago Change %

Down 25%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites